Please assess the completion status of the following clinical trial:

Trial Title: 1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 ans.~* Metastatic breast cancer or locally advanced~* RE+, HER2-~* Patient receiving paclitaxel-bevacizumab first line chemotherapy~Exclusion Criteria:~* Previous treatment by exemestane (both in adjuvant or metastatic treatment).~* 1st line of chemotherapy different thaan paclitaxel-bevacizumab.~* Treatment by paclitaxel-bevacizumab \> 18 weeks.~* HER2 positifs et/ou récepteurs aux oestrogènes négatifs.~* Previous thrombosis event within the 6 months before inclusion .~* Previous significant surgery within the 28 days before treatment start~* Previuous coagulopathy.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- paclitaxel-bevacizumab (Type: ACTIVE_COMPARATOR): Paclitaxel, 80mg/m² at d1, d8, d15 bevacizumab, 10 mg/kg at d1, d15
- exemestane-bevacizumab (Type: EXPERIMENTAL): exemestane, 25 mg daily dose bevacizumab, 15mg/kg every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).